Verteporfin-based photodynamic therapy overcomes gemcitabine insensitivity in a panel of pancreatic cancer cell lines

Lasers in Surgery and Medicine

Volumn 43, Issue 7, 2011, Pages 565-574

  Celli, Jonathan P ^a   Solban, Nicolas ^a   Liang, Alvin ^a   Pereira, Stephen P ^b   Hasan, Tayyaba ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

benzoporphyrin derivative (BPD); extracellular matrix; pancreatic ductal adenocarcinoma (PDAC); PDT; stroma

Indexed keywords

GEMCITABINE; LAMININ; PROTEIN BAX; PROTEIN BCL XL; VERTEPORFIN;

ARTICLE; BASEMENT MEMBRANE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL POPULATION; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CULTURE MEDIUM; CYTOPATHOGENIC EFFECT; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SENSITIVITY; DRUG UPTAKE; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; PANCREAS CANCER; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; WESTERN BLOTTING;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; HUMANS; MITOCHONDRIA; PANCREATIC NEOPLASMS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS;

EID: 80052058153     PISSN: 01968092     EISSN: 10969101     Source Type: Journal    
DOI: 10.1002/lsm.21093     Document Type: Article

References (50)

1. Bardeesy N, DePinho RA,. Pancreatic cancer biology and genetics. Nat Rev Cancer 2002; 2 (12): 897-909. (Pubitemid 37328891)
2. Warshaw A, Fernandez-del Castillo C,. Pancreatic carcinoma. N Engl J Med 1992; 326 (7): 455.
3. Ahrendt S, Pitt H,. Surgical management of pancreatic cancer. Oncology (Williston Park) 2002; 16 (6): 725-734.
4. Burris H III, Moore M, Andersen J, Green M, Rothenberg M, Modiano M, Cripps M, Portenoy R, Storniolo A, Tarassoff P,. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997; 15: 2403.
5. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J, Bachet JB, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M,. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825.
6. Bold RJ, Chandra J, McConkey DJ,. Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by Bcl-2 content. Ann Surg Oncol 1999; 6: 279-285. (Pubitemid 29221014)
7. Schniewind B, Christgen M, Kurdow R, Haye S, Kremer B, Kalthoff H, Ungefroren H,. Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis. Int J Cancer 2004; 109: 182-188. (Pubitemid 38240918)
8. Mackey JR, Yao SY, Smith KM, Karpinski E, Baldwin SA, Cass CE, Young JD,. Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters. J Natl Cancer Inst 1999; 91: 1876-1881.
9. Nakano Y, Tanno S, Koizumi K, Nishikawa T, Nakamura K, Minoguchi M, Izawa T, Mizukami Y, Okumura T, Kohgo Y,. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br J Cancer 2007; 96: 457-463. (Pubitemid 46215217)
10. Chu GC, Kimmelman AC, Hezel AF, DePinho RA,. Stromal biology of pancreatic cancer. J Cell Biochem 2007; 101: 887-907. (Pubitemid 47040870)
11. Garber K,. Stromal depletion goes on trial in pancreatic cancer. J Natl Cancer Inst 2010; 102: 448-450.
12. Mahadevan D, Von Hoff DD,. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther 2007; 6: 1186-1197. (Pubitemid 46711982)
13. Ohuchida K, Mizumoto K, Murakami M, Qian LW, Sato N, Nagai E, Matsumoto K, Nakamura T, Tanaka M,. Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions. Cancer Res 2004; 64: 3215-3222. (Pubitemid 38581425)
14. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK, Denicola G, Feig C, Combs C, Winter SP, Ireland-Zecchini H, Reichelt S, Howat WJ, Chang A, Dhara M, Wang L, Ruckert F, Grutzmann R, Pilarsky C, Izeradjene K, Hingorani SR, Huang P, Davies SE, Plunkett W, Egorin M, Hruban RH, Whitebread N, McGovern K, Adams J, Iacobuzio-Donahue C, Griffiths J, Tuveson DA,. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009; 324: 1457-1461.
15. Miyamoto H, Murakami T, Tsuchida K, Sugino H, Miyake H, Tashiro S,. Tumor-stroma interaction of human pancreatic cancer: Acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins. Pancreas 2004; 28: 38-44. (Pubitemid 38032243)
16. Neesse A, Michl P, Frese KK, Feig C, Cook N, Jacobetz MA, Lolkema MP, Buchholz M, Olive KP, Gress TM, Tuveson DA,. Stromal biology and therapy in pancreatic cancer. Gut 2011; 60 (6): 861-868.
17. Pereira SP,. Photodynamic therapy for pancreatic and biliary tract carcinoma. San Jose, CA, USA: SPIE; 2009. pp 71640J-1-71640-10.
18. Sandanayake NS, Huggett MT, Bown SG, Pogue BW, Hasan T, Pereira SP,. PDT for locally advanced pancreatic cancer: Early clinical results. San Francisco, California, USA: SPIE; 2010. pp 75510L-75518L.
19. Bown SG, Rogowska AZ, Whitelaw DE, Lees WR, Lovat LB, Ripley P, Jones L, Wyld P, Gillams A, Hatfield AWR,. Photodynamic therapy for cancer of the pancreas. Gut 2002; 50 (4): 549-557. (Pubitemid 34638877)
20. Ayaru L, Bown SG, Pereira SP,. Photodynamic therapy for pancreatic and biliary tract carcinoma. Int J Gastrointest Cancer 2005; 35 (1): 1-13. (Pubitemid 40458575)
21. Hasan T, Ortel B, Solban N, Moor C, Pogue B,. Photodynamic therapy of cancer. In:, Kufe DW, Wiechselbaum RR, editors. Cancer Medicine. Hamilton, Ontario: BC Decker, Inc.; 2005.
22. Celli JP, Spring BQ, Rizvi I, Evans CL, Samkoe KS, Verma S, Pogue BW, Hasan T,. Imaging and photodynamic therapy: Mechanisms, monitoring, and optimization. Chem Rev 2010; 110 (5): 2795-2838.
23. Mikvy P, Messman H, MacRobert AJ, Pauer M, Sams VR, Davies CL, Stewart JC, Bown SG,. Photodynamic therapy of a transplanted pancreatic cancer model using meta-tetrahydroxyphenylchlorin (mTHPC). Br J Cancer 1997; 76 (6): 713-718. (Pubitemid 27379736)
24. Mlkvy P, Messmann H, Regula J, Conio M, Pauer M, Millson CE, MacRobert AJ, Bown SG,. Photodynamic therapy for gastrointestinal tumors using three photosensitizers-ALA induced PPIX, Photofrin and MTHPC. A pilot study. Neoplasma 1998; 45: 157-161. (Pubitemid 28335681)
25. Brown S, Mellish K,. Verteporfin: A milestone in opthalmology and photodynamic therapy. Expert Opin Pharmacother 2001; 2 (2): 351-361. (Pubitemid 32427736)
26. Messmer KJ, Abel SR,. Verteporfin for age-related macular degeneration. Ann Pharmacother 2001; 35 (12): 1593-1598. (Pubitemid 34027462)
27. Kessel D, Luo Y,. Photodynamic therapy: A mitochondrial inducer of apoptosis. Cell Death Differ 1999; 6 (1): 28-35. (Pubitemid 29051852)
28. Ferrario A, Chantrain CF, von Tiehl K, Buckley S, Rucker N, Shalinsky DR, Shimada H, DeClerck YA, Gomer CJ,. The matrix metalloproteinase inhibitor prinomastat enhances photodynamic therapy responsiveness in a mouse tumor model. Cancer Res 2004; 64 (7): 2328-2332. (Pubitemid 38523882)
29. Ferrario A, Rucker N, Wong S, Luna M, Gomer CJ,. Survivin, a member of the inhibitor of apoptosis family, is induced by photodynamic therapy and is a target for improving treatment response. Cancer Res 2007; 67 (10): 4989-4995. (Pubitemid 46910208)
30. Ferrario A, von Tiehl K, Wong S, Luna M, Gomer C,. Cyclooxygenase-2 inhibitor treatment enhances photodynamic therapy-mediated tumor response. Cancer Res 2002; 62 (14): 3956-3961. (Pubitemid 34791059)
31. Rizvi I, Celli JP, Evans CL, Abu-Yousif AO, Muzikansky A, Pogue BW, Finkelstein D, Hasan T,. Synergistic enhancement of carboplatin efficacy with photodynamic therapy in a three-dimensional model for micrometastatic ovarian cancer. Cancer Res 2010; 70 (22): 9319-9328.
32. Duska L, Hamblin M, Miller J, Hasan T,. Combination photoimmunotherapy and cisplatin: Effects on human ovarian cancer ex vivo. J Natl Cancer Inst 1999; 91: 1557-1563. (Pubitemid 29457960)
33. Carthy CM, Granville DJ, Jiang H, Levy JG, Rudin CM, Thompson CB, McManus BM, Hunt DW,. Early release of mitochondrial cytochrome c and expression of mitochondrial epitope 7A6 with a porphyrin-derived photosensitizer: Bcl-2 and Bcl-xL overexpression do not prevent early mitochondrial events but still depress caspase activity. Lab Invest 1999; 79 (8): 953-965. (Pubitemid 29400140)
34. Granville DJ, Jiang H, An MT, Levy JG, McManus BM, Hunt DW,. Overexpression of Bcl-X(L) prevents caspase-3-mediated activation of DNA fragmentation factor (DFF) produced by treatment with the photochemotherapeutic agent BPD-MA. FEBS Lett 1998; 422 (2): 151-154. (Pubitemid 28064531)
35. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan J, Peng Q,. Photodynamic therapy. J Natl Cancer Inst 1998; 90 (12): 889-905. (Pubitemid 28304157)
36. Hasan T, Ortel B, Solban N, Pogue B,. Photodynamic therapy of cancer. In:, Kufe DW, Bast RCJ, Hait WN, Hong WK, Pollock RE, Weichselbaum RR, Holl JF, Frei EI, editors. Cancer medicine. 7th edition. Hamilton, Ontario: B.C. Decker, Inc.; 2006. pp 537-548.
37. Ulrich AB, Schmied BM, Standop J, Schneider MB, Pour PM,. Pancreatic cell lines: A review. Pancreas 2002; 24 (2): 111-120. (Pubitemid 34171286)
38. Sipos B, Moser S, Kalthoff H, Torok V, Lohr M, Kloppel G,. A comprehensive characterization of pancreatic ductal carcinoma cell lines: Towards the establishment of an in vitro research platform. Virchows Arch 2003; 442 (5): 444-452. (Pubitemid 36718311)
39. Loukopoulos P, Kanetaka K, Takamura M, Shibata T, Sakamoto M, Hirohashi S,. Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity. Pancreas 2004; 29 (3): 193-203. (Pubitemid 39304976)
40. Aveline B, Hasan T, Redmond RW,. Photophysical and photosensitizing properties of benzoporphyrin derivative monoacid ring A (BPD-MA). Photochem Photobiol 1994; 59 (3): 328-335. (Pubitemid 2065507)
41. Celli JP, Rizvi I, Evans CL, Abu-Yousif AO, Hasan T,. Quantitative imaging reveals heterogeneous growth dynamics and treatment-dependent residual tumor distributions in a three-dimensional ovarian cancer model. J Biomed Opt 2010; 15 (5): 051603.
42. Kessel D,. Promotion of PDT efficacy by a Bcl-2 antagonist. Photochem Photobiol 2008; 84 (3): 809-814. (Pubitemid 351589364)
43. Kessel D, Arroyo AS,. Apoptotic and autophagic responses to Bcl-2 inhibition and photodamage. Photochem Photobiol Sci 2007; 6 (12): 1290-1295. (Pubitemid 350191106)
44. Kessel D, Oleinick NL,. Initiation of autophagy by photodynamic therapy. Methods Enzymol 2009; 453: 1-16.
45. Runnels JM, Chen N, Ortel B, Kato D, Hasan T,. BPD-MA-mediated photosensitization in vitro and in vivo: Cellular adhesion and beta1 integrin expression in ovarian cancer cells. Br J Cancer 1999; 80 (7): 946-953. (Pubitemid 29233914)
46. Bissell MJ, Radisky D,. Putting tumours in context. Nat Rev Cancer 2001; 1 (1): 46-54. (Pubitemid 33741880)
47. Debnath J, Brugge JS,. Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer 2005; 5 (9): 675-688. (Pubitemid 41486361)
48. Shah AN, Summy JM, Zhang J, Park SI, Parikh NU, Gallick GE,. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol 2007; 14 (12): 3629-3637. (Pubitemid 350160137)
49. Desgrosellier JS, Cheresh DA,. Integrins in cancer: Biological implications and therapeutic opportunities. Nat Rev Cancer 2010; 10 (1): 9-22.
50. Sumer B, Gao J,. Theranostic nanomedicine for cancer. Nanomedicine 2008; 3 (2): 137-140. (Pubitemid 351611851)